BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 32397684)

  • 1. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
    Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
    Front Immunol; 2020; 11():581338. PubMed ID: 33123167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
    Bishop MR
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
    [No Abstract]   [Full Text] [Related]  

  • 4. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
    Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-Rodríguez L
    Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facing SARS-CoV-2 outbreak in immunotherapy era.
    Citarella F; Russano M; Pantano F; Dell'Aquila E; Vincenzi B; Tonini G; Santini D
    Future Oncol; 2020 Jul; 16(20):1475-1485. PubMed ID: 32468851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune status could determine efficacy of COVID-19 therapies.
    Cully M
    Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine storm and the prospects for immunotherapy with COVID-19.
    Calabrese LH
    Cleve Clin J Med; 2020 Jun; 87(7):389-393. PubMed ID: 32393592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity, COVID-19 and immunotherapy: the complex relationship!
    Finelli C
    Immunotherapy; 2020 Oct; 12(15):1105-1109. PubMed ID: 32677493
    [No Abstract]   [Full Text] [Related]  

  • 11. Updated Approaches against SARS-CoV-2.
    Li H; Zhou Y; Zhang M; Wang H; Zhao Q; Liu J
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The many faces of the anti-COVID immune response.
    Vardhana SA; Wolchok JD
    J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32353870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
    Zhang YY; Li BR; Ning BT
    Front Immunol; 2020; 11():2033. PubMed ID: 32922406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?-Lessons Learned From Cancer.
    Barbieri A; Robinson N; Palma G; Maurea N; Desiderio V; Botti G
    Front Immunol; 2020; 11():588724. PubMed ID: 33117402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is a "Cytokine Storm" Relevant to COVID-19?
    Sinha P; Matthay MA; Calfee CS
    JAMA Intern Med; 2020 Sep; 180(9):1152-1154. PubMed ID: 32602883
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19: The Immune Responses and Clinical Therapy Candidates.
    Zhand S; Saghaeian Jazi M; Mohammadi S; Tarighati Rasekhi R; Rostamian G; Kalani MR; Rostamian A; George J; Douglas MW
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in SARS-CoV-2: a systematic review.
    Bai YX; Xu YH; Wang X; Sun C; Guo Y; Qiu S; Ma KW
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):9208-9215. PubMed ID: 32965016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Inflammasome in Times of COVID-19.
    de Rivero Vaccari JC; Dietrich WD; Keane RW; de Rivero Vaccari JP
    Front Immunol; 2020; 11():583373. PubMed ID: 33149733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.